“…The 74 patients (53%) who received any standard, approved multiagent combination regimen had a median OS of 14 months compared to 8 months for the 47 patents (34%) who received other non-standard combinations and the 19 (13%) who received single agent therapy (P = 0.029). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The pituitary gland is not well separated from this mass and the basilar and internal carotid arteries were patent. Labs show prolactin to be >1000,testosterone and LH was low but FSH, Free T4, TSH, ACTH, am cortisol, IGF-1 were normal range. …”
Enlace del recurso
Enlace del recurso

“…Due to the rapid growth of unstructured data collections, including patent databases and particularly the scientific literature, there is a pressing need to generate, assess and expose robust big data text mining solutions to semantically enrich documents in real time. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…For type B single or double-device deployment was performed depending on an inter-defects distance. In type C and D, a patent foramen-ovale (PF) device was selectively positioned to the central defect to occlude the central defect and cover the peripheral ones. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The Chinese herbal yinang formulation (YNF), which is derived from a Chinese patent medicine, appears to have a satisfactory effect in treating ADPKD. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The NaoShuanTong capsule (NSTC), a traditional Chinese patent medicine, has been extensively used in the treatment of stroke in China. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…These projects were evaluated using both traditional and non-traditional metrics (e.g., patents, startups, publications). The initial investment of $1.5 million to fund 36 projects has led to over $88 million dollars in additional funding. …”
Enlace del recurso
Enlace del recurso

“…PURPOSE: A personalised transportable folding device for seating (DATP) on a standard seat was developed by an occupational therapist at the Toulouse University Hospital Centre (patent no. WO 2011121249 A1) based on the hypothesis that the use of a seat to assist with better positioning on any chair during meals modifies the sitting posture and has an impact on cervical statics which increases the amplitude of movements of the axial skeleton (larynx and hyoid bone) and benefits swallowing. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Erzhi Pill (EZP), a classic Chinese patent medicine, is often used to treat osteoporosis and shows a capacity for bone metabolism regulation. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Inhibition of multiple ErbB receptors may result in improved patient outcomes. EO1001 is a novel, patented, oral, brain-penetrating, irreversible pan-ErbB inhibitor targeting EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4). …”
Enlace del recurso
Enlace del recurso

“…Regarding community care seeking practices, 197 (55.8%) would first visit the health centre/hospital, followed by 91 (25.8%) traditional healer/herbalist and 35 (9.9%) pharmacy/patent medicine vendor if they develop a skin NTD. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The patient progressively became more obtunded and required constant stimuli in order to maintain a patent airway. Non-invasive positive pressure ventilation was not administered due to persistent emesis. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: GuanXinNing tablet (GXNT), a traditional Chinese patent medicine, has been found to have remarkable antithrombotic effects and can effectively inhibit pro-thrombotic factors in previous studies. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Our meta-analysis revealed that combination therapy with QY and western medicine was more effective than western medicine alone (QY vs other Chinese patent medicines: RR = 1.37, 95% Cl: 1.23∼1.52, P < 0.00001; QY + coenzyme Q10 + routine treatment vs coenzyme Q10 + routine treatment: RR = 1.20, 95% Cl: 1.14∼1.27, P < 0.00001; QY + trimetazidine + acyclovir vs trimetazidine + acyclovir: RR = 1.59, 95% Cl: 1.38∼1.83, P < 0.00001; QY + routine treatment vs routine treatment: RR = 1.09, 95% Cl: 1.03∼1.15, P < 0.003). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Results: Technical success of the TEVAR was 97.6% owing to unintentional partial coverage of supra-aortic branches in 3 cases (the vessels were patent on imaging). The stent-graft was repositioned at its intermediate diameter in 79 patients (62.2%), and the angulation feature was applied in 64 cases (50.4%), mainly to improve proximal wall apposition and orthogonality in the aorta. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Seven days after modeling, the Tuina group was treated daily with a “massage and tuina manipulation simulator” (Patent No. ZL 2007 0187403.1), which was used daily to stimulate Yinmen (BL37), Yanglingquan (GB34), and Chengshan (BL57) with point-pressing method, plucking method, and kneading method. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Up to 50% of ischemic strokes in the young after thorough diagnostic work-up remain cryptogenic or associated with low-risk sources of cardioembolism such as patent foramen ovale (PFO). We studied with cardiac magnetic resonance (CMR) imaging, whether left ventricular (LV) non-compaction—a possible source for embolic stroke due to sluggish blood flow in deep intertrabecular recesses—is associated with cryptogenic strokes in the young. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Cinobufacin is a Chinese patent medicine widely used for breast cancer in China. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…CASE PRESENTATION: A 2-day-old girl weighing 3.5 kg was admitted to our hospital with a low oxygen saturation (SpO(2)) of 70% She was diagnosed with IVI [situs ambiguous(inversus), D-loop, and D-Spiral], atrial septal defect, patent ductus arteriosus (PDA), interrupted inferior vena cava with azygos continuation to the left superior vena cava (SVC), and polysplenia by transthoracic echocardiography and cardiac computed tomography. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…ATCC 21929 has been previously associated with the production of a patented antibiotic, antibiotic 60-6 (i.e., cerexin A); however, the virulence potential and growth characteristics of this lineage have never been assessed. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso